查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602719

類澱粉沉積症治療市場：按類型、最終用戶分類 - 2025-2030 年全球預測

Amyloidosis Treatment Market by Type (Medication, Surgery), End-Users (Hospitals, Specialty Centers) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

類澱粉沉積症治療市場2023年估值為52.3億美元，預計2024年將達57.3億美元，複合年成長率為7.57%，預計到2030年將達到87.3億美元。

類澱粉沉積症治療是指用於控制類澱粉沉積症的策略和治療方法，澱粉樣變性是一種罕見疾病，其特徵是澱粉樣蛋白在器官和組織中異常累積。類澱粉沉積症治療的範圍包括藥物治療、幹細胞移植和支持性治療，每種治療的目的都是控制症狀、減緩疾病進展和改善生活品質。這些治療的必要性在於類澱粉沉積症能夠針對多種類澱粉沉積症，這些澱粉樣變性會影響心臟、腎臟、肝臟和神經系統等器官，例如 AL 和 ATTR類澱粉沉積症。治療應用範圍從醫療設施到居家醫療，最終用途包括醫院、專科診所和研究機構。市場成長主要是由藥物研究的進步、對罕見疾病的認知提高以及診斷技術的改進所推動的。特別是，隨著最近創新治療方法（例如基於RNA干擾的治療方法）的激增，新型治療方法和個人化醫療方法的開發存在重大潛在機會。然而，由於治療成本上升、疾病管理複雜性和疾病稀有性等挑戰，市場擴張受到限制。新創新的機會包括基因研究的進步，以便更好地了解疾病發病機制，以及開發用於早期診斷和治療監測的更有效的生物標記。此外，雖然市場本質上是利基市場，但持續的研究和投資已經產生了顯著的成果，為能夠提供具有成本效益和創新解決方案的新進入者鋪平了道路。創新的重點領域包括增強藥物傳輸系統、探索聯合治療以及利用人工智慧對治療結果進行預測分析。為了實現最佳業務成長，建議與監管機構合作，加速藥物核准並建立研發策略夥伴關係，並加強意識和早期診斷舉措，促進與醫療保健提供者的合作關係也很重要。

主要市場統計
基準年[2023] 52.3億美元
預測年份 [2024] 57億美元
預測年份 [2030] 87.3億美元
複合年成長率（%） 7.57%

市場動態：揭示快速發展的類澱粉沉積症治療市場的關鍵市場洞察

類澱粉沉積症治療市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助組織做出明智的投資決策、改善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 類澱粉沉積症在大量且不斷成長的人群中顯著流行
    • 提高對早期診斷和類澱粉沉積症治療的認知
    • 積極的研究活動開發新的類澱粉沉積症療法
  • 市場限制因素
    • 類澱粉沉積症藥物的高成本和報銷政策問題
  • 市場機會
    • 類澱粉沉積症治療新治療方法的出現
    • 加大對現代化醫療基礎設施的投資
  • 市場挑戰
    • 類澱粉沉積症治療的複雜性與風險

波特的五力：駕馭類澱粉沉積症治療市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解類澱粉沉積症治療市場的外部影響

外部宏觀環境因素在塑造類澱粉沉積症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解類澱粉沉積症治療市場的競爭格局

類澱粉沉積症治療市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣澱粉類澱粉沉積症治療市場供應商的績效評估

FPNV定位矩陣是評估類澱粉沉積症治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了類澱粉沉積症治療市場的成功之路

類澱粉沉積症治療市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於人口成長，類澱粉沉積症盛行率不斷增加
      • 提高對類澱粉沉積症早期診斷和治療的認知
      • 旨在開發類澱粉沉積症新治療藥物的積極研究活動
    • 抑制因素
      • 類澱粉沉積症治療的高費用和報銷政策問題
    • 機會
      • 類澱粉沉積症治療新治療選擇的出現
      • 加大現代化醫療基礎建設投入
    • 任務
      • 類澱粉沉積症治療的複雜性與風險
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章類澱粉沉積症治療市場：按類型

  • 藥物治療
    • 化療
    • 標靶治療
      • 抗血管新生治療
      • 單株抗體
      • 蛋白酶體抑制劑
  • 外科手術
    • 骨髓移植/幹細胞移植
    • 器官移植

第7章類澱粉沉積症治療市場：依最終使用者分類

  • 醫院
  • 專業中心

第8章美洲類澱粉沉積症治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區類澱粉沉積症治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲類澱粉沉積症治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie, Inc.
  • Acrotech Biopharma, Inc
  • Alexion Pharmaceuticals
  • Alnylam Pharmaceuticals Inc.
  • Arcturus Therapeutics, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Attralus, Inc.
  • BridgeBio Pharma, Inc.
  • Bristol-Myers Squibb Company
  • Corino Therapeutics, Inc.
  • GlaxoSmithKline PLC
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services Inc
  • Merck & Co., Inc.
  • Neurimmune AG
  • Oncopeptides AB
  • Pfizer Inc.
  • Proclara Biosciences Inc.
  • Prothena Corporation PLC
  • Regeneron Pharmaceuticals Inc.
  • SOM INNOVATION BIOTECH, SA,
  • Sorrento Therapeutics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-C002B1C996F0

The Amyloidosis Treatment Market was valued at USD 5.23 billion in 2023, expected to reach USD 5.70 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 8.73 billion by 2030.

Amyloidosis treatment refers to the strategies and therapies employed to manage amyloidosis, a rare disease characterized by abnormal accumulation of amyloid proteins in organs and tissues. The scope of amyloidosis treatment involves modalities such as medication, stem cell transplantation, and supportive care, each tailored to manage symptoms, slow disease progression, and improve quality of life. The necessity of these treatments is underscored by their ability to target diverse forms of amyloidosis, addressing conditions like AL amyloidosis and ATTR amyloidosis, which can affect organs including the heart, kidneys, liver, and nervous system. Applications of treatment extend from healthcare facilities to home care, with end-use spanning hospitals, specialty clinics, and research institutes. Market growth is influenced significantly by advances in pharmaceutical research, increasing awareness about rare diseases, and improved diagnostic methodologies. Key potential opportunities reside in the development of novel therapeutics and personalized medicine approaches, particularly as recent innovations such as RNA interference-based therapies gain traction. However, the market faces challenges such as high costs of treatment, the complexity of disease management, and the rarity of the condition, which limits broad market expansion. Emerging opportunities for innovation include advancements in genetic research to better understand the disease pathogenesis and the development of more effective biomarkers for early diagnosis and treatment monitoring. Further, the market's nature remains niche yet marked by significant ongoing research and investment, paving the way for new entrants who can bring cost-effective, innovative solutions. Focus areas for innovation include enhancing drug delivery systems, exploring combination therapies, and harnessing artificial intelligence for predictive analytics in treatment outcomes. For optimal business growth, aligning with regulatory pathways to expedite drug approvals and forming strategic partnerships for research and development are recommended, alongside fostering collaborations with healthcare providers to enhance awareness and early diagnosis initiatives.

KEY MARKET STATISTICS
Base Year [2023] USD 5.23 billion
Estimated Year [2024] USD 5.70 billion
Forecast Year [2030] USD 8.73 billion
CAGR (%) 7.57%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Amyloidosis Treatment Market

The Amyloidosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Significant prevalence of amyloidosis among rising gigantic population
    • Growing awareness about early diagnosis and amyloidosis treatments
    • Robust research activities to develop novel amyloidosis drugs
  • Market Restraints
    • Issues related to high cost and reimbursement policies of amyloidosis treatments
  • Market Opportunities
    • Emergence of new treatment options for treating amyloidosis
    • Rising investments to develop modernized healthcare infrastructure
  • Market Challenges
    • Complexities and risk associated with amyloidosis treatments

Porter's Five Forces: A Strategic Tool for Navigating the Amyloidosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Amyloidosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Amyloidosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Amyloidosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Amyloidosis Treatment Market

A detailed market share analysis in the Amyloidosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Amyloidosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Amyloidosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Amyloidosis Treatment Market

A strategic analysis of the Amyloidosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Amyloidosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acrotech Biopharma, Inc, Alexion Pharmaceuticals, Alnylam Pharmaceuticals Inc., Arcturus Therapeutics, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Attralus, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Corino Therapeutics, Inc., GlaxoSmithKline PLC, Ionis Pharmaceuticals, Inc., Johnson & Johnson Services Inc, Merck & Co., Inc., Neurimmune AG, Oncopeptides AB, Pfizer Inc., Proclara Biosciences Inc., Prothena Corporation PLC, Regeneron Pharmaceuticals Inc., SOM INNOVATION BIOTECH, SA,, Sorrento Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Amyloidosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Medication and Surgery. The Medication is further studied across Chemotherapy and Targeted therapy. The Targeted therapy is further studied across Anti-Angiogenesis Therapy, Monoclonal Antibodies, and Proteasome Inhibitors. The Surgery is further studied across Bone Marrow Transplantation/Stem Cell Transplantation and Organ Transplantation.
  • Based on End-Users, market is studied across Hospitals and Specialty Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Significant prevalence of amyloidosis among rising gigantic population
      • 5.1.1.2. Growing awareness about early diagnosis and amyloidosis treatments
      • 5.1.1.3. Robust research activities to develop novel amyloidosis drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Issues related to high cost and reimbursement policies of amyloidosis treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of new treatment options for treating amyloidosis
      • 5.1.3.2. Rising investments to develop modernized healthcare infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities and risk associated with amyloidosis treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Amyloidosis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Chemotherapy
    • 6.2.2. Targeted therapy
      • 6.2.2.1. Anti-Angiogenesis Therapy
      • 6.2.2.2. Monoclonal Antibodies
      • 6.2.2.3. Proteasome Inhibitors
  • 6.3. Surgery
    • 6.3.1. Bone Marrow Transplantation/Stem Cell Transplantation
    • 6.3.2. Organ Transplantation

7. Amyloidosis Treatment Market, by End-Users

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialty Centers

8. Americas Amyloidosis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Amyloidosis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Amyloidosis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Acrotech Biopharma, Inc
  • 3. Alexion Pharmaceuticals
  • 4. Alnylam Pharmaceuticals Inc.
  • 5. Arcturus Therapeutics, Inc.
  • 6. Astellas Pharma, Inc.
  • 7. AstraZeneca PLC
  • 8. Attralus, Inc.
  • 9. BridgeBio Pharma, Inc.
  • 10. Bristol-Myers Squibb Company
  • 11. Corino Therapeutics, Inc.
  • 12. GlaxoSmithKline PLC
  • 13. Ionis Pharmaceuticals, Inc.
  • 14. Johnson & Johnson Services Inc
  • 15. Merck & Co., Inc.
  • 16. Neurimmune AG
  • 17. Oncopeptides AB
  • 18. Pfizer Inc.
  • 19. Proclara Biosciences Inc.
  • 20. Prothena Corporation PLC
  • 21. Regeneron Pharmaceuticals Inc.
  • 22. SOM INNOVATION BIOTECH, SA,
  • 23. Sorrento Therapeutics, Inc.
  • 24. Spectrum Pharmaceuticals, Inc.
  • 25. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. AMYLOIDOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. AMYLOIDOSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AMYLOIDOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AMYLOIDOSIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ANTI-ANGIOGENESIS THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY BONE MARROW TRANSPLANTATION/STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 111. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 127. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 132. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 147. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 152. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 162. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 172. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 182. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 187. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 192. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 202. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 207. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 212. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 217. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 222. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM AMYLOIDOSIS TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 232. AMYLOIDOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 233. AMYLOIDOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023